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Introduction
 Hepatitis B virus (HBV) infections are a major cause 
of acute and chronic hepatitis, and of its long-term 
complications for example decompensate cirrhosis and 
hepatocellular carcinoma (HCC) (Hosaka et al., 2010). 
About 5% of the global population. almost, 350 million 
persons, are currently infected with HBV. Chronic 
hepatitis B virus infection is still an important cause of 
morbidity and mortality, as well as a source of potential 
new infection (Jeon et al., 2012). Chronic HBV carriers 
may develop chronic hepatitis, cirrhosis, and HCC with 
HBV as the most frequent cause (Jayakumar et al., 2012). 
The goal of therapy of chronic hepatitis B is to achieve 
a sustained suppression of HBV replication, to obtain 
remission of the underlying liver disease and thus prevent 
its progression towards cirrhosis and HCC (Lim et al., 
2011). Continuous viral suppression is equally essential 
in order to avoid the risk of the emergence of antiviral 
resistance. Chronic hepatitis B (CHB) patients require 
a prolonged but not a lifelong therapy, therefore data 
about its long term safety and effect are indispensable for 
the assessment of its risk and benefit treatment of CHB 
(Minde et al., 2012). Several nucleoside/tide analogues are 
available, such as lamivudine (LAM), adefovirdipivoxil 
(ADV), entecavir (ETV), and telbivudine (LdT), which act 
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as inhibitors of  HBV reverse transcriptase and decrease 
viral load in most cases (Patterson et al., 2011). ADV has 
become the treatment option for HBV infection due to its 
effect on lamivudine-resistant mutations occurring upon 
prolonged treatment. However, viral resistance to ADV 
develops and increases over time (Segovia et al., 2012). 
ADV-resistance is mainly associated with rtN236Tand 
rtA181V/T mutations within the D and B functional 
domains of  HBV polymerase been developed to detect 
ADV-resistant mutations, such as direct polymerase chain 
reaction (PCR) sequencing, INNO-LiPA, restriction 
fragment length polymorphism (PCR-RFLP), matrix-
assisted laser desorption/ionization time of  fight-mass 
spectrometry (MALDI TOF MS) with their respective 
advantages and disadvantages (Zou et al., 2009). 
Sequencing remains the best approach to the identification 
of new mutations. However, it cannot detect rtN236T and 
rtA181V/T mutations in less than 25% of a total viral 
population and is not appropriate for large-scale use in 
large cohort studies or clinical laboratories because of 
its labor intensive and time consuming manipulations 
(Liu et al., 2010). INNO-LiPA and MALDI TOF MS are 
capable of detecting variants, but more strict experiment 
conditions and equipment’s are required. PCR-RFLP 
could only detect mutations in a high proportion and is 
also labor intensive and time consuming (Osiowy et al., 
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2006; Wang et al., 2009). Monitoring of viral load will 
play an important role in assessing treatment Prolonged 
treatment with antiviral agents can lead to the emergence 
of drug-resistant virus (Chang et al., 2012). Resistance 
to lamivudine is well documented and is often associated 
with mutations in the YMDD of the HBV polymerase 
B and C domains. Adefovir is effective in suppressing 
lamivudine-resistant HBV and, therefore, is most 
commonly used in patients with lamivudine-resistant 
HBV infection (Chen et al., 2010). While acquired 
resistance to Adefovir is important, primary resistance 
to this nucleotide analogue was reported recently (Inoue 
et al., 2011). Adefovir resistance is associated with 
increased HBV DNA concentrations, HBeAg positivity 
and increased alanine transaminase (ALT) concentrations 
with exacerbation of liver disease during treatment (Tseng 
et al., 2009). Therefore, detection of mutant resistant to 
treatment is necessary to prevent disease progression and 
malignancy and recommended for rapid identification and 
sensitive treatment monitoring (Kim et al., 2010). In this 
study described a sensitive method for the detection of 
ADV-resistant HBV quasi species by ALLGIO real-time 
fluorescent PCR and evaluation development of primary 
adefovir resistance in chronic HBV patients that had been 
long-term lamivudine monotherapy in Kerman, southeast 
of Iran. So far no study has been done in this area. 
 AllGlo technology employs two identical reporter dyes 
that are attached to the ends of an oligonucleotide. Two 
dyes quench each other when the labeled oligo is in its 
free form (Liu et al., 2011). Upon hybridization with the 
target sequence, the labeled oligo becomes stretched and 
cleaved. This leads to the separation of the two reporter 
dyes and de-quench occurs. As this process releases two 
fluorescing molecules instead of one, the signal change 
is much greater, making AllGlo-based quantitative PCR 
detections highly sensitive and robust (Miszczycha et al., 
2012). Since AllGlo requires only single dye component, 
it greatly simplifies the manufacturing process. Simple, 
efficient chemistry also yields high quality and uniform 
products with much reduced cost. This makes AllGlo 
probes highly competitive on the market (Yoshida et 
al., 2008). Because AllGlo does not require a quencher 
dye, a condition that often limits the choice of reporter 
dye in traditional fluorogenic probes, AllGlo probes 
and primers can choose a wide range of absorption and 
emission wavelengths, virtually cover the entire visible 
spectrum. With these flexibilities researchers are able to 
design tailor-made multiplex assays according to their 
specific needs (Jamnikar, 2012). AllGlo technology is the 
ultimate choice for fluorogenic probe-based nucleic acid 
detection. It out performs TaqMan  and Molecular Beacon 
in signal strength, multiplexing capacity, and affordability. 
It also can be used as fluorogenic primers that compare 
favourably to current existing primer technologies such 
as Ampliphore, LUX primer. AllGlo probes is available in 
six colors, MAR, JUP, SAT, URA, NEP and PLU, which 
match with the absorption and emission wavelength 
of FAM, HEX, TAMRA, ROX, Cy5 and Quasar 670, 
respectively. These six AllGlo dye labels are compatible 
with most real time PCR instruments and generally require 
no special calibration (Wu et al., 2010).
Materials and Methods
Patient selection
 In retrospective study, seventy patients (63 males and 7 
females, mean age 44 years, range 41-66 years) who were 
diagnosed as Chronic Hepatitis B infection from October 
2010 to December 2011 in our laboratory (Virology 
Laboratory of the Besat Specialist Clinic, Kerman, IRAN) 
following the guidelines of prevention and treatment of 
chronic hepatitis B were enrolled in this study. 
 The decision to treat is primarily based on the 
combination of three criteria: a) serum HBV DNA levels, 
b) serum alanine amino transferase (ALT) levels and 
c) histological grade and stage of the underlying liver 
disease. ADV was administered with oral dipivoxil (10 
mg) for 53 weeks (range: 38-68 weeks), during which viral 
breakthrough, viral rebound, partial or inadequate virus 
response occurred. Exclusion criteria included a coexisting 
severe illness, organ or bone marrow transplantation, 
recent treatment with systemic corticosteroids, 
immunosuppressant’s or chemotherapeutic agents, liver 
disease not due to hepatitis B, and seropositivity for human 
immunodeficiency virus (Saah et al., 2003) or hepatitis C 
or D virus. 
Molecular test
 About 5 ml of peripheral blood were collected from 
each patient into EDTA-containing vacutainer tubes. 
Plasma was separated and stored at -70°C. HBV DNA 
was extracted from 200 μL of plasma with High Pure Viral 
Nucleic Acid kit (Roche Diagnostics GmbH, Mannheim, 
Germany). Extracted DNA pellets were resuspended 
in 100μL of prewarmed Elution buffer and stored at 
-20°C until use. For Quantification of HBV DNA we use 
Real Time HBV kit (artus HBV kit, Qiagen, Germany). 
Quantitative determination of the amplified products 
was done with the Rotor Gene 6,000 (Corbett Research, 
Australia). Determination of LAM and ADV resistance 
was done with specific primers and probes from the 
HBV polymerase region in YMDD motif were design by 
Dr Mollaie Using Beacon designer software (Version 8, 
Primer Biosoft, USA). Primers and probes for ALLGIO 
assay were synthesized by AlleLogic Biosciences 
(AlleLogic Biosciences Corporation, USA). Primer and 
probes sequence are shown in Table 1. All of samples were 
tested with ZNA probe assay (Malekpour and Mollaie, 
2012), then all of samples were tested with ALLGIO 
probe assay, which has been developed for detection of 
adefovir resistant mutants in our laboratory. To verify the 
results, determination of ADV and LAM resistance was 
compared with HBV adefovir and lamividine resistant 
mutants Real Time PCR Kit (Bioproducts, Mag. Th. 
Langmann GmbH). Quantitative determination of the 
amplified products was done with the Rotor Gene 6,000 
(Corbett Research, Australia)
Statistical analyses
 Chi square and Fisher’s exact Tests were used to 
analyze the data obtained by SPSS 11.5 software (SPSS 
Inc, Chicago; USA). The differences or association with 
p<0.05 were considered statistically significant.
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Results 
 Seventy patients with CHB were selected during 
about one year (2010-2011) that were treated with 
lamivudine as the first drug for 30-86 weeks (Mean= 64 
weeks) and adefovir for 12-44 weeks (Mean=26 weeks). 
Eighteen (25.7%) of whom developed LAM resistance 
mutations who six experienced virological relapse after 
discontinuation of LAM treatment. Of the seventy samples 
Sixty-one percent of patients were HBeAg Positive. Liver 
biopsy was available in 23 patients and 12 (17.1%) of them 
showed grade 3-4 fibrosis stage (Table 2). Additionally, 
three patients without liver biopsy had been classified as 
having cirrhosis based on clinical, analytical and ultra 
sonographic findings. Thus, 15 (21.4%) of 70 patients were 
classified as having severe fibrosis or cirrhosis (Figure 2). 
ALT level and HBV DNA Load were measured in two 
stages, before and after treatment with Adefovir (Figure 
3). Mean of ALT level was 310±12 IU/L and mean of 
HBV-DNA level was 8.5±1.7 log10 IU/mL. The average 
load of HBV DNA dropped to 5.6±3.2 log10 IU/mL and 
mean of ALT level dropped to 260±56 IU/L after treatment 
with ADV for 86 weeks. Significant differences in HBV-
DNA levels were observed between the patients with or 
without YMDD mutations prior to lamivudine treatment 
(6.71±0.98 versus 8.5±1.7 log10 IU/mL, respectively, 
P<0.05)(Figure 4). Of the seventy samples, Eighteen 
samples had resistance to LAM (25.7%) and eight samples 
(11.4%) had resistance to ADV therapy. Three types of 
lamivudine resistance in these samples was determined, 
Nine patients had a YIDD mutation (50%), Two patients 
had a YSDD mutation (11.1%) and seven patients had a 
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Table 1. Primer and Probes Sequences for Detection 
Adefovir Resistance
Name N236T Tm Position
Forward primer TTTACCGCTGTTACCAATTTTC 54 151
Reverse primer CAATGACCCATAACATCCAATG 54 270
Wilde type probe TATACATTTAAACCCTAACAAAACAAA 54 186
Mutant probe TATACATTTAACCCCTAACAAAACAAA 55 186
 A181V/T
Forward primer GGCTTTCGGAAAATTCCTATG 53 202
Reverse primer CCAATACCACATCATCCATATAAC 54 337
Wilde type probe CCGTTTCTCCTGGCTCAGTTTACT 59 238
Mutant probe CCGTTTCTCCTGGTTCAGTTTACT 61 238
Wilde type probe CCGTTTCTCCTGGCTCAGTTTACT 59 238
Mutant probe CCGTTTCTCCTGACTCAGTTTACT 61 238
Table 2. Baseline Characteristics of Patients
Characteristics Male Female  Total
Gender (%)  63 (90%) 7 (10%) 70 (100%)
Mean age (years) 43±8  41±9  42±8.5
HBeAg-Positive (%) 30 (47.6%) 1 (14.2%) 31 (44.2%)
F3–F4 (%)* 12 (19.0%) 0 (%) 12 (17.1%)
Cirrhosis (%) 3 (4.7%) 0 (%) 3 (4.28%)
Prior lamivudine therapy (%) 63 (100%) 7 (100%) 70 (100%)
Lamivudine resistance (%) 17 (26.9%) 1 (14.2%) 18 (25.7%)
Prior Adefovir therapy (%) 54 (85.7%) 4 (57.1%) 58 (82.8%)
Adefovir resistance (%) 8 (12.7%) 0 (0%) 8 (11.4%)
Mean ALT (IU/L) 320±15  300±10  310±12
Mean HBV-DNA 10±2.1  7±1.3  8.5±1.7
(log10 IU/mL)
*Classified by liver biopsy examination or clinical radiological findings
Figure 2. Result and Frequency of HBs-Ag, HBe-Ag 
and Liver Pathology Findings in CHB Patients in this 
Study 
Figure 3. Histogram Results of ALT and DNA HBV 
Load, Before and After Treatment with Adefovir
Figure 4. Scatter Plot of ALT Level and DNA Load in 
Patients With and Without YMDD Motif
Figure 1. Polymerase Gene Mutations Conferring 
Resistance to Nucleoside Analogs. Resistance to 
lamivudine (LAM) is conferred by mutations in the YMDD 
motif within the C domain of the polymerase. Resistance to 
Adefovir (ADV) is conferred by an A181V or T mutation, or 
an N236T mutation
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YIDD/YVDD mix mutation (38.9%).Also Three types 
of Adefovir resistance in these samples was determined, 
, four patients had a rtA181T mutation(22.2%),three 
patients had a rtN236 mutation(16.7%) , one patients 
had a rtA181V mutation (5.6%), and Ten samples had no 
mutations (55.6%). Statistical calculations on the seventy 
samples showed that there is a significant relationship 
between gender and drug resistance to lamivudine or 
Adefovir. (P Value=0.01). No difference was observed 
between the results of this method and a commercial kit. 
the positive results was lower ct than commercial kit. 
 
Discussion
Chronic infection with hepatitis B virus represents a 
global health problem, with continuing new infections 
worldwide, being an important cause of liver disease, 
morbidity, and mortality (Husic-Selimovic et al., 2012). 
The goals of therapy in HBV infected patients are to 
limit or reverse progression of the disease through 
sustained suppression of HBV replication. In chronic 
Hepatitis B infection, patients not able to clear the virus 
as judged by a positive HBsAg for six months after the 
acute episode and are known as chronic cases. In these 
patients, spontaneous clearance of HBs-Ag occurs at an 
annual rate of only 0.5-2%. Spontaneous loss of HBeAg 
and serum HBV DNA occurs in 10-15% of cases and 
Antiviral therapy of CHB patients remains a major clinical 
challenge (Jayakumar et al., 2012). Lamivudine resistance 
is associated with mutations in the highly conserved 
YMDD motif of reverse transcriptase, specifically YMDD 
mutations including YIDD and YVDD mutations. YMDD 
mutations reportedly increase from 14% in 1 year to 
38%, 49% after 2 and 3 years of treatment, respectively 
(Jiang et al., 2012). Long-term antiviral treatment is 
needed in most individuals and therefore, raises the risk 
of selecting drug-resistant mutants. Drug resistance is 
associated with Polymerase gene mutations, might be 
followed by a rise in HBV viral load and ALT levels 
with exacerbation of liver disease (Veldhuijzen et al., 
2012). Adefovir is effective in suppressing lamivudine-
resistant HBV and, therefore, is most commonly used in 
patients with lamivudine-resistant HBV infection (Zhao 
et al., 2010). The raising potent anti-HBV agents will 
be important to better combat antiviral drug resistance 
and improve the current treatment strategies to delay or 
prevent drug resistance in the long term (Foroutan et al., 
2011). Same this study has not been done in Iran, and 
the information is not available about HBV resistance 
to ADV. Several studies carried out only on resistance 
to lamivudine using other methods (PCR-RFLP). In the 
current study, the rate of YMDD mutations was 25.7% 
after one year of lamivudine treatment, and 11.4% for 
ADV, which is higher than in a previous study. However, 
it is lower than that in another study, which had YMDD 
mutations in 57.4% of Japanese patients with chronic 
hepatitis B after one year of lamivudine treatment (Wang 
et al., 2009). The current study also aimed to determine the 
association of pretreatment HBV-DNA levels and HBeAg 
status at baseline with the occurrence of YMDD mutations. 
Logistic regression analysis demonstrated that high 
pretreatment HBV-DNA levels are independent factors 
for the occurrence of YMDD mutations. These findings 
are in accordance with the results of other studies. HBeAg 
status at baseline is recognized as an independent factor for 
YMDD mutations. Thus HBeAg status at baseline is one 
of the predictors. But the results are not consistent with 
those of another study suggesting that the rate of YMDD 
mutations in HBeAg positive patients was similar to that 
in HBeAg negative patients. The present study suggests 
that pretreatment HBV-DNA levels and HBeAg status 
should be considered for patients with chronic HBV after 
lamivudine treatment. High ALT levels are thought to be 
related to a more rapid selection of YMDD mutations. The 
current study revealed no significant differences in ALT 
levels in patients with or without YMDD mutations prior 
to lamivudine treatment. Logistic regression analysis in 
our study also showed that pretreatment ALT levels are 
not predictors of YMDD mutations. Studies including the 
current one showed that high ALT levels are not related to 
the rapid selection of YMDD mutations. Thus, there are 
different findings concerning the correlation of ALT levels 
with YMDD mutations. However, ALT levels are very 
important parameters for host factors, and they should be 
monitored carefully during lamivudine treatment (Osiowy 
et al., 2006; Wang et al., 2009; Liu et al., 2010; Zhao et 
al., 2010; Hu et al., 2012). 
The results of this study show that HBV DNA levels 
during treatment as an indicator of future ADV resistance. 
ADV-resistant mutation was closely associated with HBV 
DNA levels during therapy. The risk of developing ADV-
resistant mutations in patients with long-term lamivudine 
monotherapy was high. These findings suggest that 
combination therapy of LAM and ADV could be used as 
an option for patients with LAM-resistant HBV infection. 
In this study we have developed a new method for 
detection of adefovir resistance mutant in chronic hepatitis 
B patients. this method was compared with commercial 
kit and the results show that use of ALLGIO probe assay 
can be a good alternative to conventional methods and 
compared to other methods such as TaqMan probe assay 
has a higher sensitivity. Each AllGlo probe contains two 
identical fluorogenic reporter dye, therefore it can generate 
twice as much signal as all other probe systems. Unlike 
MGB probes, do not inhibit PCR reaction even at very high 
probe concentrations. We recommend that researchers 
conduct more studies about this method for detection of 
single nucleotide mutations on drug resistance.
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